Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2007

Dyax and Trubion Expand Research Alliance

  • Dyax and Trubion Pharmaceuticals have prolonged its existing research agreement, which covers protein therapeutics and diagnostics discovery.

    In addition to the ongoing multiple-target funded research project, Dyax will now transfer its phage library to Trubion’s facility for use in identifying therapeutic leads to additional targets. This will enhanceTrubion’s ability to rapidly design and develop product candidates for a range of disease targets.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »